Probiotic Lozenges Help Reduce Radiation Side Effects

Researchers have found that Streptococcus salivarius K12 probiotic lozenges can lower the risk of radiation‑induced oral mucositis in patients receiving treatment for head and neck cancers.

Trial design and patient selection

The study was a prospective, randomized, double‑blinded, placebo‑controlled trial conducted at a single tertiary care academic medical center in China. Eligible participants were adults aged 18 to 80 with non‑metastatic head and neck tumors, an Eastern Cooperative Oncology Group performance status of 0‑2, and no recent antimicrobial use or dental problems that could affect oral health.

After screening, 160 patients were allocated equally to receive either the probiotic lozenge or a matching placebo. The lozenges contained at least 1 × 10⁹ colony‑forming units of viable Streptococcus salivarius K12 cells. Participants dissolved the lozenges three times daily and refrained from eating or drinking for one hour afterward.

Results on mucositis incidence and severity

Compared with the control arm, the probiotic group experienced a statistically significant reduction in the incidence of severe oral mucositis. The onset of mucositis was delayed, and the duration of severe symptoms was shorter. Although the study did not reach statistical significance for secondary outcomes, the test arm showed numerically lower use of analgesics and reduced need for intravenous fluids or total parenteral nutrition.

Saliva analyses revealed a shift toward a more favorable oral microbiome in the probiotic cohort, with decreased levels of anaerobic pathogens that are often implicated in mucosal inflammation. Adverse events were mild and limited to gastrointestinal discomfort; no severe reactions were reported in either group.

These findings suggest that modulating the oral microbiota with a targeted probiotic can have a protective effect during radiotherapy, which traditionally damages the mucosal lining and predisposes patients to painful ulcers.

The trial highlights growing interest in microbiome‑based interventions for oncology supportive care. While the exact mechanisms remain under investigation, the reduction in harmful bacteria and the promotion of commensal species may help preserve mucosal integrity, thereby easing the burden of treatment‑related side effects.

Implications for clinical practice

Radiation therapy for head and neck malignancies often leads to oral mucositis in more than half of patients, affecting eating, speaking, and overall quality of life. Current management strategies focus on pain control and nutritional support, but preventive options are limited. The probiotic lozenge offers a simple, non‑invasive approach that could be integrated into standard care protocols, provided that the results are replicated in larger, multi‑center studies.

Physicians considering this option should verify that patients have no contraindications such as recent antibiotic exposure or existing oral infections, as these factors could influence the probiotic’s effectiveness. Ongoing monitoring of oral health and microbiome composition may become part of routine assessments if such interventions gain wider acceptance.

Overall, the trial adds to a body of evidence that emphasizes the role of the oral microbiome in treatment tolerance. By targeting a specific bacterial strain, clinicians may be able to mitigate one of radiotherapy’s most debilitating side effects without adding significant risk.